Acute Intermittent Porphyria: A Deep Dive into Medical Diagnosis and Management

Introduction

The term ‘Porphyria’ originates from the ancient Greek word ‘porphura,’ signifying purple, alluding to the color of porphyrins. Porphyrins are essential precursors in the synthesis of heme, a critical component of hemoglobin responsible for oxygen transport in blood. Hemoglobin, within its globular protein subunits, houses a heme group containing an iron atom that binds to oxygen. The intricate heme synthesis pathway relies on specific enzymes at each step. Porphyrias, therefore, are a group of distinct clinical syndromes arising from deficiencies or defects in these enzymes, each impacting a specific stage of heme production. Traditionally categorized based on the predominant system affected (cutaneous versus neurohepatic), these syndromes often exhibit significant overlap with mixed symptoms.

The clinical presentation, severity, and prognosis of porphyrias are largely determined by the specific enzyme deficiency and the resulting accumulation of heme precursors or porphyrins. Acute intermittent porphyria (AIP) stands out as the most prevalent and severe form of acute porphyria. Other acute porphyrias include hereditary coproporphyria (HCP), variegate porphyria (VP), and the extremely rare 5-aminolevulinic acid (ALA) dehydratase deficiency porphyria (Doss porphyria).[](https://www.statpearls.com/Bookshelf/opens in new window/27443.media/image1.jpg) “Illustration depicting the heme synthesis pathway, highlighting the enzymes involved and the steps affected in different types of porphyria.”

AIP, like most porphyrias, follows an autosomal dominant inheritance pattern. Characteristically, acute porphyrias such as AIP present with sudden episodes of neurovisceral symptoms, often remaining latent for extended periods. AIP attacks are marked by abdominal pain, neuropathies, and constipation. Distinctively, unlike many other porphyrias, AIP does not cause a cutaneous rash. The fundamental enzymatic defect in AIP lies in the deficiency of porphobilinogen-deaminase, also known as hydroxymethylbilane synthase (HMBS), the third enzyme in the heme synthesis pathway. These acute attacks are triggered by the uncontrolled upregulation of the ALA synthase enzyme. Medical diagnosis of AIP is often delayed due to the nonspecific nature of its symptoms, which can mimic various other conditions. Currently, orthotopic liver transplantation remains the only definitive cure.[](https://www.statpearls.com/Bookshelf/opens in new window/27443.media/image2.jpg) “Diagram illustrating the enzyme deficiency in Acute Intermittent Porphyria (AIP) within the heme synthesis pathway, emphasizing the accumulation of porphyrin precursors.”

Etiology of Acute Intermittent Porphyria

Acute intermittent porphyria arises from mutations in the HMBS gene, responsible for approximately 50% reduction in HMBS enzyme activity. This gene is located on chromosome 11q24.1-q24.2. To date, 391 HMBS gene mutations have been identified.[](https://www.statpearls.com/Bookshelf/opens in new window/27443.media/image3.jpg) “Chromosome diagram showing the location of the HMBS gene on chromosome 11q24.1-q24.2, the gene responsible for Acute Intermittent Porphyria.” This deficiency becomes clinically significant during acute attacks, when the liver’s heme pool is depleted, leading to the induction of delta-aminolevulinic acid synthase 1 (ALAS1). This process results in the accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), the immediate precursors upstream of HMBS in the heme synthesis pathway.

Several factors can induce acute AIP attacks, including alcohol consumption, infections, low caloric intake, hormonal fluctuations related to the menstrual cycle, and certain high-risk porphyrogenic drugs. The Norwegian Porphyria Centre (NAPOS), in collaboration with the European Porphyria Network (Epnet), has compiled a list of medications that should be avoided in patients with porphyria. These include drugs such as ketamine, thiopental, chloramphenicol, erythromycin, nitrofurantoin, rifampicin, trimethoprim/sulfamethoxazole, spironolactone, methyldopa, valproic acid, carbamazepine, phenytoin, phenobarbital, primidone, and risperidone. Careful medication history is crucial in Aip Medical Diagnosis and management.

Epidemiology of Acute Intermittent Porphyria

The estimated combined prevalence of all acute porphyrias is approximately 5 cases per 100,000 individuals. Porphyria cutanea tarda (PCT), characterized by prominent cutaneous symptoms, is the most common porphyria overall, with an estimated prevalence of 1 in 10,000. AIP, the most common acute porphyria, has a European prevalence of about 1 in 20,000, with a higher incidence of 1 in 1,000 in Sweden due to a founder effect. Founder effects, correlating with higher AIP prevalence in specific ethnic groups in Argentina and Spain, have also been reported recently.

Acute intermittent porphyria is considered a low-penetrance genetic metabolic disease, with penetrance estimated to be around 10% to 20%. In the general population, excluding specific AIP clusters, penetrance is estimated to be less than 1%. Manifest AIP (MAIP) is diagnosed when carriers experience typical acute neurovisceral attacks accompanied by elevated porphyrin precursors. In the absence of clinical episodes, it is termed latent AIP (LAIP). While higher penetrance is associated with specific mutations, the overall genetic factors determining penetrance remain largely unknown.

AIP affects women more frequently than men, with a ratio of approximately 1.5 to 2:1. Attacks are rare before puberty, and the typical age of symptom onset is between 18 and 40 years. Understanding these epidemiological factors is important for considering AIP in differential medical diagnosis, particularly in women of reproductive age presenting with unexplained abdominal pain and neurological symptoms.

Pathophysiology of Acute Intermittent Porphyria

Acute attacks of AIP are more common in women, especially post-puberty. These attacks are typically triggered by factors such as certain drugs, infections, fasting, alcohol, and steroid hormones, as previously mentioned.

In AIP, neurological damage is thought to result from the accumulation of porphyrin precursors, porphobilinogen, and aminolevulinic acid (ALA). This AIP-associated neurological damage manifests as peripheral and autonomic neuropathies, as well as psychiatric disturbances.

The precise mechanism by which elevated levels of PBG and ALA lead to symptomatic disease remains unclear. Intriguingly, most individuals with the genetic defect remain asymptomatic despite excessive porphyrin secretion.

A 2017 case-control study involving 50 patients indicated a possible association between AIP and systemic inflammation. Storjord et al. found that levels of insulin, C-peptide, prealbumin, and markers of kidney function were decreased only in symptomatic AIP patients, not in asymptomatic carriers. They suggested that reduced insulin release in symptomatic AIP patients may be associated with increased disease activity and impaired kidney function. Further research is needed to fully elucidate the complex pathophysiology of AIP and its triggers, which is vital for improving aip medical diagnosis and targeted therapies.

History and Physical Examination in AIP

Acute attacks of acute intermittent porphyria typically last up to a week, with symptom progression often following a pattern: abdominal pain, followed by psychiatric symptoms, and finally peripheral neuropathies.

Abdominal pain is a hallmark symptom, usually described as severe, epigastric, and colicky. It can persist for several days and may be accompanied by constipation and vomiting.

Patients can present with a wide range of psychiatric symptoms, including depression, often concurrent with abdominal and/or neurological symptoms. A Swedish study indicated an increased risk of schizophrenia or bipolar disorder in individuals with AIP and their relatives.

Peripheral neuropathies can manifest as weakness, often starting in the lower extremities and ascending, although any nerve distribution can be affected. This presentation can mimic Guillain-Barré syndrome (GBS). Autonomic neuropathies can lead to hypertension and tachycardia.

Central nervous system signs may include delirium, weakness progressing to quadriplegia and respiratory failure, cortical blindness, and even coma. Seizures can occur in about 5% of cases, with partial seizures being the most common type. Red or brown urine, which darkens upon exposure to air, light, and warmth, may be observed. It is important to note that AIP, unlike porphyria cutanea tarda, does not have cutaneous manifestations.

While traditionally patients were thought to be symptom-free between attacks, recent data suggests that 20% to 64% may experience chronic disabling symptoms such as pain, nausea, fatigue, and neuropathic features like numbness and tingling. A thorough history and physical examination, focusing on these characteristic symptoms, is critical for initial suspicion and guiding aip medical diagnosis.

Evaluation and Diagnostic Approach for AIP

The medical diagnosis of acute intermittent porphyria relies on detecting elevated porphobilinogen (PBG) in a random urine sample protected from light. Diagnostic confirmation should include quantitative measurement of PBG, ALA, and total porphyrins from the same urine sample. Normal urinary PBG levels are 0 to 4 mg/L, but during an acute AIP attack, levels can rise dramatically to 50 to 200 mg/L for PBG and 25 to 100 mg/L for ALA.

A urinary PBG level within the normal range (0 to 4 mg/L) during acute symptoms strongly suggests that acute porphyria is not the cause of neurovisceral symptoms.

Although urine collection for PBG and ALA quantification is ideally done during the peak of an acute attack, it can be performed within days to weeks after an episode due to the persistent elevation of urinary ALA and PBG for months to years following an attack. The exception is timed urine collection after a 4- to 5-day course of intravenous heme treatment.

Elevated urine porphyrins, particularly coproporphyrin (due to spontaneous polymerization of PBG in urine), are often observed. However, nonspecific elevation of urine porphyrins, especially coproporphyrins (1 to 2 times the reference range), is common and not specific to porphyria. Stool porphyrins are typically normal or only mildly elevated.

Increased plasma porphyrin, confirmed by a fluorescence emission scan peak at 619 nm, may be present. Molecular and DNA testing for HMBS gene mutations is not necessary for initial aip medical diagnosis but is valuable for family screening and confirming the specific genetic defect.

Associated Laboratory Abnormalities During an Acute Attack:

• Hyponatremia (most common electrolyte abnormality)
• Hypomagnesemia (also frequent)
• Mild elevations in liver aminotransferases
• Mild leukocytosis

Differentiating Between Acute Porphyrias

The symptomatology of acute porphyrias often overlaps significantly, making clinical differentiation between AIP, hereditary coproporphyria (HCP), and variegate porphyria (VP) challenging. While robust evidence-based diagnostic strategies to distinguish between these conditions are still developing, emerging approaches are promising.

Plasma Fluorescence Staining

Unlike AIP, HCP, and other porphyrias where sera from biochemically active individuals exhibit emission peaks around 619 to 620 nm, serum from VP patients contains a unique porphyrin-peptide with a peak fluorescence at approximately 626 nm when excited by 410 nm light (the Soret band). This difference in fluorescence at physiological pH can be utilized to differentiate VP from other acute and cutaneous porphyrias.

Emerging Role of Genetic Mutation Analysis in Diagnostic Confirmation

Genetic testing is increasingly important in refining the medical diagnosis of aip and other acute porphyrias. Commercial labs now offer genetic testing to identify the specific type of acute porphyria by sequencing the genes known to be defective in these conditions:

Gene/Type of Acute Porphyria

• ALAD / ALAD-deficient porphyria (Doss porphyria)
• HMBS / AIP
• CPOX / HCP
• PPOX / VP

Next-generation sequencing (NGS) is evolving in porphyria diagnostics. Researchers have designed panels containing genes like ALAS1, HMBS, CPOX, and PPOX for mutational analysis of AIP, HCP, and VP, promising more rapid and comprehensive aip medical diagnosis.

Treatment and Management Strategies for AIP

Initial and Symptom-Oriented Treatment

Given the symptom overlap between acute intermittent porphyria and various abdominal, metabolic, and neuropsychiatric conditions, confirming the medical diagnosis of aip is paramount for effective management.

Avoiding precipitating factors, especially drugs, is crucial and should be thoroughly emphasized to patients and their families.

For confirmed AIP patients presenting with an acute attack, the initial approach typically involves high carbohydrate intake, either orally or intravenously with dextrose, to suppress hepatic ALAS1 transcription. Intravenous administration of 10% dextrose in 0.45% saline should be initiated promptly. If the patient is not severely ill with weakness, vomiting, or hyponatremia, a 48-hour trial of a high carbohydrate diet before starting specific treatment is currently recommended.

For pain management, parenteral opiates like morphine, diamorphine, and fentanyl are preferred. Nausea and vomiting can be managed with prochlorperazine, promazine, and ondansetron. These symptoms usually begin to subside within 72 to 96 hours. Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers (diltiazem) are used to treat tachycardia and hypertension. Seizures, if present, can be controlled with diazepam, magnesium sulfate, or clonazepam.

Specific Treatment: Intravenous Heme Therapy

Intravenous heme administration is the specific therapy for acute AIP attacks. Heme replenishes the hepatocyte heme pool and downregulates ALAS1, reducing porphyrin precursor production and alleviating symptoms. Heme achieves this by downregulating ALAS1 transcription, destabilizing mRNA, or blocking mitochondrial import of the mature enzyme.

Due to the delayed effect of heme therapy on reducing plasma ALA and PBG levels, intravenous heme therapy (IHT) should be initiated promptly for severe acute attacks and continued for four days (3 to 4 mg/kg of heme/day). Clinical response, typically indicated by a decrease in urine and serum PBG, is usually observed by the third day. Panhematin administration should be through a large peripheral vein or central line to minimize the risk of phlebitis, which can also be reduced by preparing it with human albumin instead of water. Other potential complications include a transient increase in prothrombin time and increased hepatic iron production. Patient discharge is considered when parenteral opioids are no longer required, and the patient can tolerate oral medications.

While generally well-tolerated, recurrent IHT carries risks that healthcare providers must be aware of.

Risks Associated with Recurrent Intravenous Heme Therapy

Recurrent IHT can lead to several significant issues: the need for repeated venous access, increasing the risk of thromboembolic disease, liver fibrosis, hepatic iron overload, and the development of therapeutic ‘tolerance’ to heme infusion. Research indicates that heme infusion can induce hepatic heme oxygenase 1 (HMOX1) expression. HMOX1, the key enzyme in heme catabolism, when induced by heme therapy, can reduce the hepatocyte heme pool, paradoxically leading to enhanced ALAS1 expression. This heme-induced auto-catabolic effect can contribute to the tolerance observed in some patients.

Orthotopic Liver Transplantation: Definitive Cure

Currently, orthotopic liver transplantation (OLT) is the only established cure for acute intermittent porphyria, with reported survival rates around 80%. However, a significant risk (40%) of hepatic artery thrombosis associated with OLT has led to recommendations to reserve this procedure for patients with severe, recurrent acute attacks and significantly impaired quality of life (QoL).

Potential and Experimental Therapies for AIP

Ongoing research is exploring alternative therapies for AIP, currently in various phases of clinical trials:

Enzyme Replacement Therapy (ERT): Based on successful reduction of plasma PBG accumulation in AIP mouse models using recombinant human HMBS/PBGD (rhPBGD), the European Medicines Agency (EMA) granted rhPBGD orphan designation in 2002. Clinical trials in healthy subjects, asymptomatic HMBS-deficient individuals, and AIP patients with repeated attacks have been conducted. While rhPBGD effectively detoxified PBG metabolites, limitations included its short half-life and lack of liver targeting.

Liver Gene Therapy: Clinical trials are evaluating two gene therapy strategies for AIP: HMBS-gene therapy and RNA interference to inhibit ALAS1 gene expression. HMBS-gene therapy involves delivering the HMBS gene to hepatocytes using viral vectors. The ALAS1-targeted approach utilizes small interfering RNA (siRNA) to reduce delta-ALA production. Both strategies are still in clinical trial phases, awaiting larger trials to confirm consistent efficacy and safety before potential approval. These emerging therapies hold promise for future aip medical diagnosis and management.

Differential Diagnosis of AIP

In an observational study of acute porphyrias involving 90 AIP patients, the average diagnostic delay was a significant 15 years. Given that acute abdominal pain is a common presenting symptom of AIP attacks, patients often undergo appendectomies or cholecystectomies before porphyria is considered or diagnosed.

Due to the broad range of neuro-visceral clinical presentations in AIP, the differential diagnosis list is extensive:

1. Other acute porphyrias: Clinically distinguishing AIP from other acute porphyrias like HCP, VP, and Doss porphyria can be challenging.
2. Causes of acute abdomen: Peritonitis, appendicitis, acute cholecystitis, acute gastritis, acute pancreatitis, intestinal obstruction, strangulated abdominal hernia, acute mesenteric ischemia, ileus, diverticulitis, esophagitis, endometriosis, gastric outlet obstruction, intussusception, pelvic inflammatory disease, ovarian cysts, acute pyelonephritis, aortic dissection.
3. Lead poisoning: This is a significant differential, and assessing for anemia and blood lead levels is crucial for differentiation.
4. Conditions associated with autonomic neuropathy: Hypertensive crisis, tachyarrhythmias, adrenal crisis, familial Mediterranean fever, fibromyalgia.
5. Neuropsychiatric conditions: Acute psychotic episodes, delirium, panic attacks, Guillain-Barré syndrome. A comprehensive approach to aip medical diagnosis requires considering and excluding these differential diagnoses.

Prognosis of Acute Intermittent Porphyria

The prognosis for acute intermittent porphyria is generally good with early recognition and timely treatment. Mortality rates during acute attacks have decreased significantly over recent decades, now ranging from 5% to 20%, due to advancements in aip medical diagnosis and treatment. However, in cases resistant to heme therapy or with recurrent attacks, orthotopic liver transplantation remains the only currently approved method to reduce mortality.

Ongoing clinical trials exploring ERT and liver gene therapy offer hope for further improving the prognosis of AIP in the near future.

Long-term complications of AIP, including arterial hypertension, chronic kidney disease, neurological deficits, and an increased risk of hepatocellular carcinoma, necessitate close monitoring and patient follow-up.

Complications of AIP

(This section was intentionally left blank in the original article, but complications are mentioned in the Prognosis section. Common complications include:)

• Chronic kidney disease
• Arterial hypertension
• Neurological deficits (chronic neuropathy, paralysis)
• Hepatocellular carcinoma (increased lifetime risk)
• Recurrent acute attacks leading to diminished quality of life

Deterrence and Patient Education

AIP is a rare, autosomal dominant condition characterized by a chronic course with recurrent acute neurovisceral symptom episodes. Ongoing research is aimed at finding a definitive cure for this lifelong disease. Once aip medical diagnosis (or diagnosis of another acute hepatic porphyria) is confirmed, patients should receive thorough counseling. This includes detailed education about trigger factors that can precipitate attacks, with specific lists of safe and unsafe medications. Patients need to understand that current treatments primarily address acute attacks, and the best strategy for remaining asymptomatic is preventing exposure to known precipitants. They should be instructed to seek immediate medical attention at the emergency department if abdominal pain develops. Education on prognosis, potential complications, and the importance of genetic testing for offspring is also essential.

Enhancing Healthcare Team Outcomes in AIP Management

Clinicians should maintain a high index of suspicion for acute intermittent porphyria in patients presenting with unexplained abdominal pain and neuropsychiatric symptoms. Patients with AIP, due to recurrent acute abdominal pain, may initially be seen by surgeons and potentially undergo unnecessary surgical procedures. Therefore, surgical teams should be aware of AIP as a non-surgical cause of severe acute abdomen and maintain suspicion in patients with recurrent attacks or those exhibiting neuropsychiatric symptoms.

Effective aip medical diagnosis and management require an interprofessional team approach, involving primary care physicians, nurse practitioners, metabolic/genetic disease experts, hematologists, biochemists, pharmacists, nursing staff, and surgeons. Early diagnosis is crucial to minimize long-term complications. Clinical geneticists are paramount for providing genetic counseling to AIP patients regarding family planning, discussing inheritance risks, prenatal testing options, and early identification of carrier status in offspring. Nurses play a vital role in administering heme therapy, monitoring treatment progress, and observing for adverse reactions, promptly informing the clinical team of any issues. Pharmacists should verify medication dosages, conduct thorough medication reviews to identify potential drug interactions and porphyria-precipitating drugs, and communicate any concerns to the medical team. Open communication and collaborative teamwork among all interprofessional team members are essential to mitigate the significant morbidity associated with AIP.

Review Questions

(The review questions section was omitted as per instructions to only include title and content)

References

1. Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute Hepatic Porphyrias: Review and Recent Progress. Hepatol Commun. 2019 Feb;3(2):193-206. PMC6357830 PubMed: 30766957
2. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-14. PMC4562648 PubMed: 26366103
3. Fontanellas A, Ávila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med. 2016 Nov 02;18:e17. PubMed: 27804912
4. Szlendak U, Bykowska K, Lipniacka A. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. Adv Clin Exp Med. 2016 Mar-Apr;25(2):361-8. PubMed: 27627571
5. Roveri G, Nascimbeni F, Rocchi E, Ventura P. Drugs and acute porphyrias: reasons for a hazardous relationship. Postgrad Med. 2014 Nov;126(7):108-20. PubMed: 25387219
6. Ramanujam VS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015 Jul 01;86:17.20.1-17.20.26. PMC4640448 PubMed: 26132003
7. Cerbino GN, Gerez EN, Varela LS, Melito VA, Parera VE, Batlle A, Rossetti MV. Acute intermittent porphyria in Argentina: an update. Biomed Res Int. 2015;2015:946387. PMC4449928 PubMed: 26075277
8. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010 Mar 13;375(9718):924-37. PubMed: 20226990
9. Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, Balwani M, Doheny D, Peter I, Chen R, Desnick RJ. Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. Hum Mutat. 2016 Nov;37(11):1215-1222. PMC5063710 PubMed: 27539938
10. Storjord E, Dahl JA, Landsem A, Fure H, Ludviksen JK, Goldbeck-Wood S, Karlsen BO, Berg KS, Mollnes TE, W Nielsen E, Brekke OL. Systemic inflammation in acute intermittent porphyria: a case-control study. Clin Exp Immunol. 2017 Mar;187(3):466-479. PMC5290301 PubMed: 27859020
11. Sardh E, Barbaro M. Acute Intermittent Porphyria. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Sep 27, 2005. PubMed: 20301372
12. Cederlöf M, Bergen SE, Larsson H, Landén M, Lichtenstein P. Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden. Br J Psychiatry. 2015 Dec;207(6):556-7. PubMed: 26494868
13. O’Malley R, Rao G, Stein P, Bandmann O. Porphyria: often discussed but too often missed. Pract Neurol. 2018 Oct;18(5):352-358. PubMed: 29540448
14. Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, Howe DL, Hungate JR, Kim JB, Agarwal S, Marquis P. Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. Patient. 2018 Oct;11(5):527-537. PMC6132435 PubMed: 29915990
15. Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol. 2014 Jan;67(1):60-5. PubMed: 23908454
16. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E., Gruppo Italiano Porfiria (GrIP). A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias. Eur J Intern Med. 2014 Jul;25(6):497-505. PubMed: 24809927
17. Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. J Emerg Med. 2015 Sep;49(3):305-12. PubMed: 26159905
18. Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013 Jan;3(1):365-401. PubMed: 23720291
19. Barman-Aksözen J, Suter L, Wegmann F, Meienberg J, Minder AE, Beer M, Komminoth P, Minder EI, Schneider-Yin X. A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias. Scand J Clin Lab Invest. 2019 Sep;79(5):305-313. PubMed: 31154864
20. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 Aug 31;377(9):862-872. PubMed: 28854095
21. Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem. 2006 Apr;52(4):650-6. PubMed: 16595824
22. Willandt B, Langendonk JG, Biermann K, Meersseman W, D’Heygere F, George C, Verslype C, Monbaliu D, Cassiman D. Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD Rep. 2016;25:77-81. PMC5059188 PubMed: 26093628
23. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986 Jul 24;315(4):235-8. PubMed: 3724815
24. Doberer D, Haschemi A, Andreas M, Zapf TC, Clive B, Jeitler M, Heinzl H, Wagner O, Wolzt M, Bilban M. Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol. 2010 Dec;161(8):1751-62. PMC3010580 PubMed: 20718734
25. Dover SB, Moore MR, Fitzsimmons EJ, Graham A, McColl KE. Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology. 1993 Aug;105(2):500-6. PubMed: 8335204
26. Yasuda M, Erwin AL, Liu LU, Balwani M, Chen B, Kadirvel S, Gan L, Fiel MI, Gordon RE, Yu C, Clavero S, Arvelakis A, Naik H, Martin LD, Phillips JD, Anderson KE, Sadagoparamanujam VM, Florman SS, Desnick RJ. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. Mol Med. 2015 Jun 05;21(1):487-95. PMC4607616 PubMed: 26062020
27. Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN., UK Liver Selection and Allocation Working Party. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012 Feb;18(2):195-200. PMC3472026 PubMed: 21618697
28. Johansson A, Möller C, Fogh J, Harper P. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement. Mol Med. 2003 Sep-Dec;9(9-12):193-9. PMC1430985 PubMed: 15208740
29. Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. PubMed: 17375984
30. Prieto J, Gonzalez-Aseguinolaza G. Acute Intermittent Porphyria: Novel Etiologic and Pathogenic Therapies Based on RNA Transfer to the Liver. Hepatology. 2019 Sep;70(3):1061-1063. PubMed: 31026336
31. Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, Bossi K, Gandolfo L, Light C, Bishop D, Desnick RJ. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014 Dec;127(12):1233-41. PMC4563803 PubMed: 25016127
32. Pallet N, Mami I, Schmitt C, Karim Z, François A, Rabant M, Nochy D, Gouya L, Deybach JC, Xu-Dubois Y, Thervet E, Puy H, Karras A. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015 Aug;88(2):386-95. PubMed: 25830761
33. Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand). 2009 Feb 16;55(1):66-71. PubMed: 19268004
34. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol. 2012 Nov;65(11):976-80. PubMed: 22851509
35. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 Nov 23;377(21):2101. PubMed: 29166231

Disclosures

Disclosure: Luis Gonzalez-Mosquera declares no relevant financial relationships with ineligible companies.

Disclosure: Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.